-
Posted by
Two Blokes 11 hours ago -
Filed in
Stock
-
1 view
Shares of Sarepta Therapeutics declined 16.5% to $18.32 in premarket trading on Friday after a Bloomberg report that a patient enrolled in an early-stage study of one of the company's gene therapies has died from acute liver failure.
